YIV-906, combined with standard neoadjuvant chemoradiation for locally advanced rectal cancer, markedly decreased severe gastrointestinal toxicity. The study enrolled 24 patients, achieving a 16.7% complete or near-complete response rate and a median overall survival of 74.9 months. Notably, acute grade 3 diarrhea occurred in only 8.3% of cases, indicating a potential benefit in managing treatment-related side effects in this patient group.
• Why it matters: To minimize severe GI toxicity during neoadjuvant therapy interruptions
Journal Article by Verma N, Johung KL (…) Higgins SA et 10 al. in J Gastrointest Oncol
2024 Journal of Gastrointestinal Oncology. All rights reserved.